

Seelos Therapeutics

15:08 06 Dec 2019

Roth applauds Seelos' shift towards major depressive disorder with SLS-002; rates shares 'Buy'

Broker Roth Capital Partners applauded New York clinical-stage biopharmaceutical company Seelos Therapeutics Inc's (NASDAQ:SEEL) recent shift towards using its drug SLS-002 to treat major depressive disorder (MDD) rather than post-traumatic stress disorder (PTSD).

Roth analysts view MDD as a "more substantial commercial opportunity" and potential for quicker trial enrollment. The broker reiterated a 'Buy' rating for the stock.

Analyst Yasmeen Rahimi noted that Seelos received FDA fast track designation for SLS-002 for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) on November 18.

READ: Seelos starts dosing in Phase I PK/PD study of SLS-002 intranasal ketamine depression drug

"This development not only highlights FDA's recognition of the high unmet need for MDD patients, but also allows for more frequent communication with the FDA and potential for Accelerated Approval or Priority Review, which could expedite SLS-002's path to approval," said the analyst.

Seelos was quick to execute, added Rahimi, and announced dosing of the first patients on November 20 in a Phase I drug-drug interaction (DDI) study to show the drug can be safely administered with two commonly prescribed antidepressants over 14 days.

And on November 27, the group announced first dosing in a Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) two part study in 62 healthy volunteers.

PK/PD data will be critical for establishing safety of SLS-002, said Roth, which added that strong data here would be key for establishing dosing and de-risking the upcoming POC (proof of concept) study in MDD suicidality.

Notice of allowance

This week, Seelos won a notice of allowance for another US patent for SLS-005 (trehalose) - its investigational molecule targeting a number of neurodegenerative conditions.

"In our view, this patent strengthens SEEL's position in addressing neurodegenerative diseases, and adds another wall of patent protection for trehalose," said Rahimi.

Roth reiterated a \$8 share target on the stock, which is around eight times' the current price of \$1.04, up 6.6% on Friday in New York.

This target is derived from a risk-adjusted net present value analysis, based on \$5.90 per share for SLS-002 for acute

Price: 0.8123

Market Cap: \$43.27 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: SEEL

Listing: NASDAQ

52 week	High	Low
	1.705	0.42

Sector: Pharma & Biotech

Website: seelostherapeutics.com

Company Synopsis:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.

action@proactiveinvestors.com

suicidality in the US; \$0.90 per share for SLS-005 for Sanfilippo in US and \$0.80 a share for SLS-005 for OPMD, which is a type of muscular dystrophy, which has 20,000 patients worldwide, said the broker.

Sanfilippo Syndrome is a rare genetic condition in which the body doesn't have certain enzymes to break down long chains of sugar molecules and it can cause fatal brain damage.

SLS-005 is currently under an open-label Phase 2B study, fully funded by the Team Sanfilippo Foundation.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).